UPDATE: Brean Capital Assumes Akebia Therapeutics (AKBA) at Buy

September 29, 2016 7:13 AM EDT
Get Alerts AKBA Hot Sheet
Price: $9.54 +0.10%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AKBA Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
(Updated - September 29, 2016 9:38 AM EDT)

Brean Capital assumed coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $18. Analyst Difei Yang is bullish on the company's vadadustat for treating anemia.

"Phase 2b data on vadadustat is quite impressive," said Yang. "Not including revenues from the MTPC deal, Akebia held cash and cash equivalents of about $189 mil, which should fund the company’s operations through 2Q17. International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone. Moving forward, with both Phase III trials underway and potential European partnership around the corner, the company can focus on its second clinical candidate, AKB-6899, an orally administered HIF stabilizer. The AKB-6899 Phase I trial will enroll a wide range of tumor patients and we project data to be released in 2H17. We like Akebia's asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care. As such, we assume coverage with a BUY rating and $18 TP." said Yang."

For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.

Shares of Akebia Therapeutics closed at $9.08 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Brean Capital

Add Your Comment